Yen-Chin Chen
Tainan, 722, Taiwan
NCT Number: NCT04403971
Chlorhexidine is a effective strategy in reducing ventilator associated pneumonia. However, it is unclear if prophylactic 0.12% chlorhexidine oral rinse can reduce the risk of non-ventilator hospital-acquired pneumonia among hospitalized patients.
Looking for future studies?
Notify Me20 year–100 year
All sexes
Interventional
Not applicable
Tainan, 722, Taiwan
Participants will be classified into three groups, applied twice a day by care givers. Oral colonization will be tested in the baseline, day-3, day-7, and at the discharge. Quantitation of colonization of the oral cavity by oral rinses and respiratory pathogens were measured.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
The control group received 10ml normal saline for oral rinse twice a day.
Time frame: 1 year
Time frame: 1 year
National Cheng-Kung University Hospital
Other
Effect of 0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia Among Hospitalized Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial DetailsNCT04153682
Cross Infection, Disease Attributes
Créteil, France
View Trial DetailsNCT05483309
Cross Infection, Disease Attributes
Liverpool, United Kingdom
View Trial DetailsNCT04774094
Cross Infection, Disease Attributes
Fuyang, Anhui, China
View Trial Details